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The development of prevention therapies for Alzheimer’s disease (AD) would greatly benefit 
from biomarkers that are sensitive to the subtle brain changes that occur in the preclinical stage 
of the disease. Reductions in the cerebral metabolic rate of glucose (CMRglc), a measure of 
neuronal function, have proven to be a promising tool in the early diagnosis of AD. In vivo 
brain 2-[18F]fluoro-2-Deoxy-D-glucose-positron emission tomography (FDG-PET) imaging de-
monstrates consistent and progressive CMRglc reductions in AD patients, the extent and topo-
graphy of which correlate with symptom severity. There is increasing evidence that hypo-
metabolism appears during the preclinical stages of AD and can predict decline years before 
the onset of symptoms. This review will give an overview of FDG-PET results in individuals at 
risk for developing dementia, including: presymptomatic individuals carrying mutations res-
ponsible for early-onset familial AD; patients with Mild Cognitive Impairment (MCI), often a 
prodrome to late-onset sporadic AD; non-demented carriers of the Apolipoprotein E (ApoE) ε4 
allele, a strong genetic risk factor for late-onset AD; cognitively normal subjects with a family 
history of AD; subjects with subjective memory complaints; and normal elderly followed long-
itudinally until they expressed the clinical symptoms and received post-mortem confirmation of 
AD. Finally, we will discuss the potential to combine different PET tracers and CSF markers of 
pathology to improve the early detection of AD.  J Clin Neurol  2009;5:153-166
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Introduction 
 
Alzheimer’s disease (AD) is the most common form of de-
mentia in the elderly and is the fourth leading cause of death 
in individuals over age 65 after heart disease, cancer, and st-
roke.
1 AD is a progressive neurodegenerative disorder with 
insidious onset and characterized by severe decline in episo-
dic memory. Instrumental signs include aphasia, apraxia, and 
agnosia, together with general cognitive symptoms, such as 
impaired judgment, decision-making, and orientation.
2 Cur-
rently, there are no available tests for the definitive diagnosis 
of AD in vivo and the clinical diagnosis of AD remains a be-
havioral diagnosis after the exclusion of other causes. This 
greatly limits the potential for early intervention and preven-
tion research. Furthermore, it is estimated that between 50% 
and 90% of dementia cases are left undiagnosed by standard 
clinical examinations.
3 
The definitive diagnosis of AD is based on the post-mor-
tem observation of specific pathological lesions: intracellular 
neurofibrillary tangles (NFT), amyloid beta (Aβ) deposition in 
the form of extracellular senile plaques and blood vessel de-
posits, associated with neuronal and synaptic loss, and brain 
atrophy in specific brain areas.
4,5 Neurodegeneration in AD is 
estimated to begin as many as 20-30 years before the clinical 
manifestations become evident.
6-9 During this preclinical ph-
ase, plaque and tangle load increase, and the first symptoms 
appear after specific brain circuits are structurally disrupted 
through synapse loss and neuronal death (see
10 for review). It 
is widely recognized that the brain regions most vulnerable 
in early AD are in the medial temporal lobes [MTL, i.e., hip-
pocampus, and transentorhinal, entorhinal cortex (EC), and 
subiculum].
6,7,9 The pyramidal cells anatomically connected 
to the EC and the CA1 and subiculum regions of the hippo-
campus are particularly prone to NFT formation and degener- 
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ation, whereas primary sensory-motor, occipital areas, and ce-
rebellum exhibit minimal neuronal loss.
6,7,9 Disruption of the 
pyramidal neurons in the perforant path is thought to discon-
nect the hippocampus from the rest of the cortex, strongly 
contributing to the decline in memory observed in early AD.
11 
While there appears to be significant overlap between cere-
brovascular disease and AD pathology,
12,13 a neuropatholo-
gical definition for mixed forms of dementia remains to be 
established. 
There is an association between NFT staging and severity 
of clinical status in AD. NFTs originate in the MTL, which 
plays a critical role in the neural control of memory functions, 
and then begin to cluster in the adjacent inferior temporal and 
posterior cingulate cortex (PCC) in mild AD, further disrupt-
ing episodic and autobiographic memory. In moderate to 
severe dementia, NFTs develop within the parieto-temporal 
and prefrontal association cortices, which are involved in the 
neural control of perception, attention, and language.
6,7 Des-
pite an initial predilection for the neocortex, Aβ depositions 
are also found in the MTL at later stages of disease.
14-16 For 
many years, the aggregation of large Aβ fibrils was consider-
ed the key event in AD pathogenesis and the main determin-
ant of neuronal degeneration.
17 A recent reformulation of the 
amyloid cascade hypothesis states that Aβ oligomers (Aβ-
derived diffusible ligand, ADDL), not fibrillar Aβ, confer 
greater neurotoxicity to neurons by disrupting nerve signal-
ing pathways and subsequently causing neuronal cell death.
18 
While the causes of neurodegeneration in AD are under 
investigation, the early appearance of pathological lesions and 
the progressive nature of cognitive deterioration in AD indi-
cate a great need for developing biological markers of dis-
ease that are sensitive to the brain changes that are expected 
to occur decades prior to the onset of clinical symptoms. Ide-
ally, a biological measure would be predictive of AD in pre-
symptomatic individuals. Criteria for an ideal biomarker of 
the disease have been proposed by the Consensus Group on 
Molecular and Biochemical Markers of AD.
19 In short, a mo-
del biomarker for the disease should detect a fundamental ch-
aracteristic of the neuropathology and be validated in neuro-
pathologically confirmed cases, with sensitivity and speci-
ficity of no less than 80%.
19 
Several modalities show promise in the development of 
early diagnostic tools for AD. These include: magnetic re-
sonance imaging (MRI) measurements, positron emission to-
mography (PET) imaging of glucose metabolism in the MTL, 
PET imaging of Aβ deposits, and cerebrospinal fluid (CSF) 
biomarkers for tauopathy and Aβ. At present, none of these 
are recommended in any consensus guidelines for the diag-
nosis of AD, as they are not yet validated by large prospec-
tive studies.   
Structural imaging, such as MRI, plays an important part 
in the diagnosis of AD by identifying other causes of demen-
tia, such as tumor, subdural hematoma, and cerebrovascular 
diseases marked by infarcts and white-matter lesions.
2 Ce-
rebral atrophy, visualized as enlarged ventricles and cortical 
sulci, can also be identified by CT and MRI, but there is signi-
ficant overlap with normal aging and other dementias.
20 None-
theless, several CT and MRI studies have shown that MTL 
atrophy is an early sign of AD and has value in predicting future 
dementia in non-demented subjects (see, among others).
21-25 
In addition to predicting future AD, hippocampal atrophy is 
also apparent in vascular cognitive impairment and can be 
useful in predicting cognitive decline related to vascular de-
mentia.
26 
Ultimately, AD pathology has the effect of impairing neu-
ronal function, which then leads to the clinical symptoms of 
dementia. Functional neuroimaging offers the unique capab-
ility to both visualize the direct effects of neuronal activity 
and quantify the rates of specific biological processes at the 
tissue level in vivo. PET imaging with 2-[18F]fluoro-2-Deo-
xy-D-glucose (FDG) has long been used to track AD-related 
brain changes by providing qualitative and quantitative esti-
mates of the cerebral metabolic rate of glucose (CMRglc). 
Glucose is the predominant source of energy for the brain. 
Early studies showed that glucose utilization is not only mea-
surable, but also serves as an index of neuronal function.
27 
Brain energy metabolism is mainly associated with brain glu-
tamate signaling,
28 as more than 80% of brain’s neurons are 
excitatory and 90% of synapses are glutamatergic. Thus, glu-
cose metabolism can be interpreted as an index of synaptic 
functioning and density.
27,29-31 A recent animal study using 
FDG-PET showed a significant correlation between CMRglc 
in vivo and levels of synaptophysin, a marker of synaptic den-
sity, assessed at post-mortem.
31 Additionally, astrocytes in 
the extraneuronal space have metabolic demands and contri-
bute to the FDG-PET signal.
32,33 Recent studies have shown 
that coupling between energy metabolism and neuronal acti-
vity may also be achieved through astrocytic uptake of glu-
cose and lactate shuttling to neurons.
33  
The present review will provide an overview of FDG-PET 
studies in AD, with an emphasis on the presymptomatic and 
preclinical detection of AD. 
 
Alterations of Brain Glucose 
Metabolism in Alzheimer’s Disease 
 
One of the striking features of AD is the drastic reduction of 
CMRglc in specific brain regions. FDG-PET studies in AD 
demonstrate consistent and progressive CMRglc reductions, 
whose extent and topography correlate with symptoms seve- 
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rity (see
34 for review). FDG-PET studies report that, as com-
pared to age-matched healthy normal controls, AD patients 
show regional metabolic reductions in the parieto-temporal
35,36 
and posterior cingulate cortices,
37 against a background of 
widespread global metabolic impairment.
38 The severity and 
topography of the metabolic reductions may also vary accord-
ing to the age of onset of AD.
39 Late-onset AD patients may 
be more likely to show mild metabolic reductions in the in-
ferior temporal gyri, rather than extensive hypometabolism 
in the parieto-temporal regions, which are more typically ob-
served in early-onset AD.
39 CMRglc reductions are also ap-
parent in the frontal lobe in advanced disease.
40 This pattern 
of hypometabolism is seen in contrast to relative preservation 
of the primary motor and visual areas. Moreover, the cere-
bellum, thalamus and basal ganglia nuclei are spared from 
significant reductions in glucose metabolism.
41 In compari-
son to AD, normal aging is characterized by subtle and diffuse 
CMRglc reductions in the frontal cortex and anterior cin-
gulate cortex (ACC), accompanied by slight reductions in 
global CMRglc.
42 
These FDG-PET findings were initially reported in the 
early 1980’s and have since been replicated numerous times. 
Furthermore, the pattern of hypometabolism described is lar-
gely accepted as a reliable in vivo hallmark of AD. Studies 
show that temporo-parietal abnormalities have high sensi-
tivity in distinguishing AD from normal aging, despite some 
regional overlap.   
These characteristic CMRglc reductions have also been 
used to differentiate AD from other neurodegenerative diseases, 
such as frontotemporal and Lewy body dementia (LBD),
43 
and cerebrovascular disease.
44 
One of the major challenges of the field remains to disen-
tangle the relative contributions of AD, vascular cognitive im-
pairment and, to a lesser extent, LBD to different stages of 
cognitive impairment in the general population.   
 
The Early Diagnosis  
of Alzheimer’s Disease 
 
Importantly, MTL CMRglc reductions have been observed 
on FDG-PET before the onset of AD symptoms and a grow-
ing list of observations has highlighted the importance of 
PET as a tool for the detection of early disease and for esti-
mating an increased risk for future dementia. This list of ob-
servations includes (Table 1):  
• Presymptomatic individuals carrying autosomal domi-
nant mutations responsible for early-onset familial AD;  
• Patients with Mild Cognitive Impairment (MCI), which is 
in many cases a prodrome to AD;  
• Cognitively normal elderly who declined to MCI and AD 
several years after PET scan acquisition;  
• Cognitively normal individuals carriers of the Apolipo-
protein E (ApoE) E4 allele, a susceptibility factor for late-
onset AD;  
• Cognitively normal subjects with subjective memory com-
plaints; 
• Cognitively normal subjects with a maternal family his-
tory of AD. 
The main FDG-PET findings from these studies are re-
viewed below. 
 
Conversion Studies 
 
Presymptomatic early-onset familial Alzheimer’s 
disease 
Autosomal dominant mutations have been identified in three 
Table 1. Preclinical diagnostic findings 
At-risk group  Control group  PET findings  References 
Presymptomatic  
Early-onset Familial AD 
Mutation Non-carriers  • Whole brain hypometabolism 
• Parieto-temporal, PCC, frontal cortex,   
• and MTL hypometabolism 
48, 46, 47 
 
NL ApoE-4 Carriers 
  (ApoE-4 +) 
NL ApoE-4 Non-carriers 
(ApoE-4 -) 
• Parieto-temporal, PCC, thalamus, and frontal 
• cortex hypometabolism 
• Greater CMRglc decline over time 
73, 74, 75, 76,
  77, 78, 79 
NL with Subjective Memory 
 Complaints (SMC +) 
NL without Subjective 
 Memory  Complaints (SMC -) 
• Parieto-temporal and MTL hypometabolism  79 
NL with a Maternal Family 
  History of AD (FHm) 
Normal Individuals without a Maternal 
  Family History of AD (FH- and FHp) 
• Parieto-temporal, PCC, frontal cortex, and MTL 
• hypometabolism 
• Greater CMRglc decline over time 
85, 86 
 
NL-MCI & NL-AD  NL-NL  • MTL hypometabolism when NL 
• Parieto-temporal and PCC hypometabolism   
• at time of decline 
• Greater CMRglc decline over time 
49, 68, 50 
 
 
AD: Alzheimer’s disease, NL: cognitively normal subjects, MCI: mild cognitive impairment, PCC: posterior cingulate cortex, CMRglc:
cerebral metabolic rate of glucose, MTL: medial temporal lobes. 
  
 
 
 
 
Early Detection of AD 
  156 J Clin Neurol  2009;5:153-166
genes, i.e., amyloid precursor protein (APP, on chromosome 
21), Presenilin 1 (PS1, on chromosome 14), and Presenilin 2 
(PS2, on chromosome 1), which are associated with early-
onset familial AD (FAD). FAD accounts for <5% of AD cases 
in the general population and is characterized by autosomal 
dominant inheritance with 100% penetrance and a specific 
early age of symptom-onset for a given pedigree (see
45 for 
review). Therefore, the study of presymptomatic mutation car-
riers, close to the expected age of dementia onset provides 
unique information about preclinical AD-related brain ch-
anges in individuals who are destined to develop the disease. 
Several FDG-PET studies examining presymptomatic FAD 
have shown parieto-temporal, posterior cingulate, and frontal 
cortex hypometabolism in most FAD cases, as compared to 
age-matched controls.
46,47 A study by Kennedy et al.
47 showed 
that whole-brain CMRglc in presymptomatic FAD individuals 
is intermediate between controls and symptomatic FAD pa-
tients, suggesting a progression of global CMRglc impair-
ment throughout the course of disease. However, these early 
studies examined only the neocortex. They did not examine 
the MTL, nor did they perform partial volume correction of 
the FDG-PET values. Since these patients also showed signi-
ficant atrophy on MRI, it remained to be established whether 
the CMRglc reductions were an effect of an increasing CSF 
pool or if they reflect functional deficits in the remaining tis-
sue. Unfortunately, CSF is not resolved by the PET camera 
and therefore cannot be avoided in tissue sampling. As a re-
sult, partial volume effects of CSF lower CMRglc values ob-
tained with FDG-PET.   
We recently addressed this issue in an FDG-PET and MRI 
study of presymptomatic PS-1 carriers from families with 
early-onset FAD, examined an average of 13 years prior to 
the estimated age at disease onset.
48 Our data show MTL and 
cortical hypometabolism in presymptomatic FAD, as com-
pared to age-matched non-carriers from the same families. 
Furthermore, these CMRglc reductions in FAD individuals 
exceeded tissue loss. Specifically, we compared CMRglc and 
volumes in several brain regions, including the hippocampus, 
EC, PCC, parietal and temporal cortices, and the whole-br-
ain. Significant volume reductions in FAD as compared to 
controls were restricted to the parietal cortex. Conversely, 
CMRglc reductions on FDG-PET were observed in all regions 
examined and remained significant after MRI partial volume 
correction. After partial volume correction, the CMR glc re-
ductions ranged from 13% (whole brain) to 21% (PCC), re-
flecting true reductions of brain glucose utilization per unit 
brain volume. After partial-volume correction, MTL CMRglc 
values were reduced by 12% in the hippocampus and 20% in 
the EC. Overall, presymptomatic FAD patients displayed wide-
spread CMRglc reductions in the brain regions typically hy-
pometabolic in clinically diagnosed dementia patients. In con-
trast, structural brain atrophy was relatively absent in these 
individuals.
48 These results provide definitive evidence that 
CMRglc reductions precede clinical symptoms as well as 
gross structural brain changes. Similar observations have been 
made in the preclinical stages of late-onset AD.
49,50 Fore a 
more detailed discussion on the value of PET relative to st-
ructural MRI, see.
20 
 
Mild cognitive impairment 
A successful strategy to examine the preclinical stages of spo-
radic AD has been to investigate MCI patients. MCI is re-
cognized by many as a transitional state between healthy ag-
ing and dementia, during which individuals are able to per-
form the usual activities of daily living, but suffer mild mem-
ory impairments and/or other cognitive difficulties exceed-
ing those expected on the basis of normal aging. These symp-
toms reduce the quality of life for the patient and put them at 
higher risk for developing AD.
51,52 In particular, patients in 
research settings having salient memory deficits, e.g., amnes-
tic MCI, decline to AD with an estimated conversion rate of 
10-30% per year.
51,52 
While parieto-temporal and PCC hypometabolism is con-
sensually recognized as the metabolic signature of AD, there 
is currently no specific pattern of hypometabolism consider-
ed to be a hallmark for MCI, as related to AD (see
20,34 for re-
cent reviews). In keeping with the concept of MCI as an in-
termediate stage along the hypothesized continuum from 
normal aging to AD, MCI patients generally present with mild 
global and regional hypometabolism within the same brain 
regions typically affected in clinical AD,
37,49,53-62 including an 
increasing numbers of reports of MTL CMRglc reductions. 
The regional patterns of CMRglc reductions in MCI are 
milder and more variable than those found in AD and cor-
respond to variations in the patterns of cognitive and beha-
vioral abnormalities in individual patients.
62,63 Importantly, 
FDG-PET studies in MCI showed that hippocampal hypo-
metabolism is a consistent feature of MCI patients regardless 
of the neuropsychological profile.
49,50,55,61 Studies have shown 
a more diversified metabolic profile in non-amnestic MCI 
(i.e., patients with selective deficits in attention and langu-
age
51) who show either an absence of cortical hypometabol-
ism or hypometabolism in brain regions including, but not 
restricted to the anterior cingulate and parieto-temporal cor-
tices.
49,55,61,64,65 In contrast, amnestic MCI patients more con-
sistently show pronounced abnormalities in the parieto-tem-
poral cortices and PCC.
37,56-58,66 Therefore, early metabolic 
reductions in the PCC may represent a more specific marker 
of AD than hippocampal hypometabolism.
58 Given the high-
er rate of decline to AD in amnestic compared to non-amne- 
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stic MCI,
52 these data suggest that more severe and spatially 
extended CMRglc reductions in AD-specific regions may pre-
dispose these patients to develop AD in the near future. 
In addition to cross-sectional examination of FDG-PET in 
the differentiation of MCI from normal aging, a growing body 
of longitudinal FDG-PET examinations has examined the 
predictive value of these measures in the decline from MCI 
to AD. These studies, most of which focused on amnestic 
MCI patients, demonstrated that baseline CMRglc reduc-
tions are more pronounced in MCI who progress to AD, as 
compared to MCI who remained stable. The reported pre-
diction accuracies range from 75% to 100%.
37,53,54,57,60,62 Mo-
reover, there is evidence showing that the metabolic changes 
in declining MCI patients are progressive and that longitu-
dinal CMRglc measures both predict and correlate with de-
cline to AD.
58 
 
Decline from normal cognition to mild cognitive 
impairment and to Alzheimer’s disease 
Very little work has been done with FDG-PET to monitor the 
progression from normal aging to sporadic AD. Such studies 
are limited because of the intrinsic difficulty of observing 
clinical change for a group with a low incidence of decline 
(1-3%/year) and a slow progression of cognitive deteriora-
tion.
67 Following cognitively normal persons over time until 
they develop dementia requires large subject samples, long 
follow-up intervals, and great expense.   
Few published FDG-PET studies have monitored decline 
from normal to MCI
49 or from normal to MCI and demen-
tia.
50,68 In the first study, de Leon et al.
49 studied 67 normal 
elderly, 48 of whom completed a 3-year follow-up. Within 
the longitudinal subgroup, 11 declined to MCI and one to 
AD. The results showed that reduced baseline CMRglc in 
the EC predicted a future diagnosis of MCI with 83% sensi-
tivity and 85% specificity. Moreover, longitudinal CMRglc 
reductions were found in the EC, hippocampus, and lateral 
temporal cortex during the progression to MCI. Importantly, 
these effects remained significant after correcting the CMRglc 
values for MRI partial volume effects, suggesting that these 
early CMRglc reductions in MCI are independent of tissue 
loss and represent true reductions of glucose consumption 
per gram of brain tissue. However, considering that many 
MCI remain stable, it was not established whether the ob-
served CMRglc reductions in MCI were in fact due to AD.   
In 2006, Jagust and colleagues
68 also looked at early meta-
bolic changes in cognitively normal individuals studied lon-
gitudinally. Sixty subjects were followed for a mean of 4 
years and received baseline FDG-PET scans and annual ev-
aluations of global cognition, assessed by the Modified Mini-
Mental State Examination (MMSE). Within this cohort, six 
subjects developed incident dementia or cognitive impair-
ment after the initial visit. The results showed that baseline 
CMRglc reductions in the angular gyri, left mid-temporal gy-
rus, and left middle frontal gyrus predicted rate of change on 
the MMSE, and were associated with faster cognitive decline.
68 
We recently published the first longitudinal FDG-PET st-
udy monitoring the conversion from normal cognition to AD. 
Mosconi et al. examined 77 normal elderly who were follow-
ed over 6-14 years and received multiple FDG-PET exami-
nations. Over this interval, 11 baseline normal subjects de-
veloped dementia, 6 of whom were diagnosed with AD, and 
19 declined to MCI. Decline for both outcome groups oc-
curred, on average, 8 years after the baseline exam. CMRglc 
in the hippocampus and cortical regions were examined as 
predictors and correlates of change in clinical status. The ba-
seline hippocampal CMRglc was the only regional predictor 
of future cognitive decline and predicted decline from nor-
mal to AD with 81% accuracy, including two post-mortem 
confirmed AD cases. The baseline hippocampal CMRglc 
also predicted decline from normal to MCI with 71% accu-
racy and from normal to another dementia with 77% accu-
racy. Hippocampal hypometabolism was also a significant 
predictor of the time to decline. On survival analysis, for in-
dividuals with hippocampal CMRglc ≤24 μmol/100 g/min, 
the predicted time to decline to AD was 7 years. For hippo-
campal CMRglc of 25-29 μmol/100 g/min, the predicted 
time to decline was 9.5 years, and for CMRglc ≥30 μmol/ 
100 g/min, greater than 14 years. In AD, for every unit dec-
rease in baseline hippocampal CMRglc, the time to decline 
decreased by 8.7% [95% CI: 3.0-14.1%] [χ2 (1)=8.6, p=0.003], 
which corresponds to a time ratio (TR) of 1.1 (95% CI: 1.0-
1.4) years; the time to decline to other dementias is decreas-
ed by 4.7% (95% CI: 0.3-8.9%) [χ2 (1)=4.6, p<0.05], for a TR 
of 1.0 (95% CI: 0.8-1.2) years; the time to decline in MCI is 
decreased by 7.2% (95% CI: 2.8-11.5%) [χ2 (1)=9.93, p<0.01], 
for a TR of 1.08 years (95% CI: 1.03-1.11). Furthermore, nor-
mal subjects who later declined experienced greater rates of 
hippocampal, PCC and temporal cortex CMRglc reductions, 
as compared to non-declining subjects.
69 
In addition, these FDG-PET data provided direct evidence 
for a topographical progression of CMRglc abnormalities, 
which appear to originate in the MTL during the normal 
stages of cognition, extend to the PCC at the MCI stage, and 
finally spread to the parieto-temporal cortices in advanced 
dementia,
50 in keeping with NFT pathology findings.
9 
Overall, our results demonstrated an association between 
reduced hippocampal CMRglc during normal aging, shor-
ter time intervals until the onset of dementia, and increased 
risk for cognitive decline, years in advance of the clinical 
diagnosis.  
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Risk Factors for Alzheimer’s Disease 
 
Apolipoprotein E E4 genotype 
The epsilon 4 allele of the ApoE gene on chromosome 19 is 
a widely recognized genetic risk factor for late-onset AD.
70,71 
The ApoE gene codes for the production of lipoproteins, 
which mediate the transport of lipids throughout bodily fl-
uids such as blood and CSF. ApoE is specifically thought to 
maintain neuronal homeostasis by transporting lipids such as 
cholesterol and phospholipids, which are responsible for neu-
ronal plasticity, throughout the central nervous system.
72 ApoE 
also provides lipids necessary for the repair of damaged nerve 
cell membranes. There are three common isoforms of the 
ApoE allele, including ApoE-2, ApoE-3, and ApoE-4. The 
ApoE-4 genotype has been designated as a risk factor for AD 
since 40% of AD patients have at least one ApoE-4 allele 
and there is also a negative association between the dose of 
ApoE-4 allele and the mean age of onset of AD.
71  
The mechanisms by which the ApoE-4 allele confers in-
creased risk of future AD is under study, although it is be-
lieved that ApoE-4 may confer decreased plasticity of neu-
ronal synapses and an inability to repair damaged neurons, 
as compared to the other allelic variants.
72  
FDG-PET studies examining the effects of the ApoE-4 al-
lele on CMRglc in non-demented individuals reported that, 
compared to non-carriers, ApoE-4 carriers have mild but de-
finite CMRglc reductions in the same regions as clinically 
affected AD patients.
73-79 There is evidence in middle-age 
ApoE-4 carriers that the metabolic reductions are progres-
sive and correlate with reductions in cognitive perform-
ance.
73,76 One study showed a 25% decline in CMRglc over 
an interval of 2 years in cognitively normal persons carrying 
two ApoE-4 alleles.
76 Moreover, the same pattern of hypo-
metabolism was observed in 20-40 year-old carriers. These 
CMRglc reductions are considered the earliest brain abnor-
malities yet found in living persons at risk for AD.
77 
Nonetheless, these studies are limited by the relatively 
short follow-up intervals and it remains to be established 
whether the CMRglc reductions in ApoE-4 carriers are pre-
dictive of decline to AD. 
 
Subjective memory complaints 
Subjective memory complaints (SMC) are widespread in the 
elderly community with a prevalence of 25-50%. For many, 
these complaints represent a preclinical sign of incipient 
dementia.
80 We recently published an FDG-PET study ex-
amining CMRglc in cognitively normal individuals with and 
without SMC.
79 The results showed that normal individuals 
with SMC have significant CMRglc reductions in several 
brain regions, including the parahippocampal gyri (PHG), 
parieto-temporal and inferior frontal cortices, fusiform gyrus, 
and thalamus, as compared to demographically matched in-
dividuals with no such complaints. Hypometabolism in the 
PHG region, which anteriorly includes the EC,
81 was the 
most significant predictor of SMC status. These reductions 
distinguished subjects with and without SMC with 75% ac-
curacy and an odds ratio of 2.4 (95% CI=1.3-4.8, p<0.001). 
In other words, normal individuals with SMC are more than 
twice as likely to have PHG deficits, as compared to those 
with no complaints.
79 Moreover, we also explored the effects 
of ApoE genotype on CMRglc and showed a significant in-
teraction between SMC and ApoE status. Among subjects 
with SMC, carriers of the ApoE-4 genotype had the lowest 
CMRglc measures in the PHG, temporal and frontal cortices, 
and thalamus, as compared to the three other subgroups. Again, 
the CMRglc reductions were most prominent in the PHG 
(18%). 
 
Maternal family history of Alzheimer’s disease 
After advanced age, the most prominent demographic risk 
factor for developing AD is a first-degree family history of 
late-onset AD.
71 Normal individuals with a first-degree re-
lative affected with AD, particularly those with an affected 
parent, have a 4- to 10-fold increased risk for developing 
AD.
82-84 We recently performed the first imaging study to 
compare individuals with and without a parental history of 
AD. In this analysis, we also examined the effects of mater-
nal and paternal history of AD on CMRglc in normal indi-
viduals.
85 Specifically, we examined the FDG-PET scans of 
49 cognitively normal elderly grouped according to their fa-
mily history of AD. We compared individuals with a mater-
nal (FHm), paternal (FHp), or no family history of AD (FH-). 
The results showed that FHm individuals have CMRglc re-
ductions in the PCC/precuneus, parieto-temporal and frontal 
cortices, and MTL, as compared to FHp and FH- individu-
als.
85 Intriguingly, these brain regions are typically affected 
in clinical AD patients. The results remained significant after 
accounting for other potential risk factors for AD, such as 
age, female gender, ApoE genotype, and presence of subjec-
tive memory complaints. The ApoE-4 genotype was repre-
sented in 22% of our FHm subjects and the same effects 
were found in the group of ApoE-4 non-carriers.   
As a follow-up to our cross-sectional study, we examined 
66 cognitively normal subjects, which included 37 FH-, 9 
FHp, and 20 FHm. These groups were controlled for age, 
education, prevalence of subjective memory complaints, and 
ApoE genotype.
86 We compared CMRglc across FH groups 
at baseline, 2-year follow-up, and longitudinally. FHm show-
ed significantly greater reductions in CMRglc in the PCC, 
parieto-temporal lobes, and MTL at baseline and follow-up  
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when compared to FHp and FH-.
86 The reductions in FHm 
increased from 13% at baseline to 23% at follow-up in the 
same brain regions and this increase in severity was signifi-
cant. In comparison, there was no significant difference be-
tween CMRglc at baseline and follow-up in FHp and FH-. 
Additionally, the mean annual decline in CMRglc for FHm 
(-3.14±1.3 μmol/100 g/min) was significantly greater than 
that observed in FH- (-0.75±1.5  μmol/100 g/min) and in 
FHp (-0.56±0.91 μmol/100 g/min) (p<0.001).
86 The progres-
sive hypometabolism seen in FHm is similar to that seen in 
ApoE-4 carriers, although the observed CMRglc reductions 
are independent of ApoE genotype. This evidence suggests 
an alternative mechanism by which FHm increases vulner-
ability to brain glucose hypometabolism. According to our 
previous PET findings, these CMRglc reductions may pre-
dispose FHm individuals to developing AD in the future. 
However, as with the ApoE-4 genotype, it is necessary to 
longitudinally follow subjects in all family history categories 
to determine whether the observed CMRglc alterations truly 
predict the onset of AD. 
The biological and genetic mechanisms that underlie the 
CMRglc reductions in individuals with a maternal family 
history of AD are not known. With all that is known about 
the molecular processes involved in glucose metabolism, 
hypometabolism may be due to, among other factors, a com-
bination of defective mitochondrial function and possible 
mitochondrial DNA (mtDNA) mutations.
87 mtDNA is en-
tirely maternally inherited in humans and diseases associated 
with mtDNA mutations often present as sporadic disorders.
87 
These pieces of evidence lend support to a mtDNA transmis-
sion hypothesis. Although other genetic mechanisms (i.e., 
epigenetic imprinting, chromosome X transmission, and mu-
tations in nuclear DNA affecting mitochondrial function) 
could potentially account for our findings, our findings sug-
gest maternal transmission of hypometabolism in normal sub-
jects at risk for AD.   
Combining PET Tracers 
 
Overall, the addition of other PET tracers to FDG-PET may 
be of use in the early detection of AD. An effective strategy 
to increase the diagnostic accuracy in AD would be to com-
bine the sensitivity of FDG-PET with another modality that 
provides a disease-specific measure of pathology. Recently, 
several PET tracers for Aβ plaques have been developed. 
The best known tracer, N-methyl-[11C]2-(4’-methylamino-
phenyl)-6-hydroxybenzothiazole, also known as Pittsburgh 
Compound-B (PIB), binds to Aβ plaques in the brain.
88 Se-
veral PIB-PET studies demonstrated significant PIB reten-
tion in AD patients as compared to controls, mostly evident in 
the middle- and pre- frontal cortex, parieto-temporal regions, 
PCC/precuneus, occipital lobes, thalamus and striatum (Fig. 
1).
88-92 These regions are consistent with the known pattern 
of Aβ plaque deposition observed at post-mortem, and cor-
relate with reductions in CSF Aβ1-42.
93 PIB-PET studies 
have shown significant PIB retention in the AD patients, and 
in as many as 61% of MCI
90-92 and 22% of normal elderly.
92 
One follow-up PIB-PET publication indicates a lack of longi-
tudinal progression,
94 suggesting that amyloid deposition may 
plateau at the AD stage. At this early stage of development, 
PIB-PET has also been shown to facilitate an improved dif-
ferential diagnosis of different dementias.
92,95 Although, a re-
cent study suggested that PIB may not be specific for dense, 
classical plaques.
96 PIB appears to bind to a family of amy-
loid substrates ranging from diffuse plaques to plaques in the 
vascular system (i.e., cerebral amyloid angiopathy), as well 
as NFT.
97 These data, together with the observation that many 
normal elderly have brain amyloid deposits, suggest that PIB-
PET imaging may be more suitable to rule out AD, since a 
patient without PIB uptake is unlikely to have AD.   
The 20-minute radioactive decay half-life of 
11C limits the 
use of PIB to centers with an on-site cyclotron, which makes 
it difficult to employ the tracer in clinical practice. To over-
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MRI FDG-PET  PIB-PET 
Fig. 1. Two representative cases: magnetic resonance
image (MRI, left column), FDG-PET (middle column)
and PIB-PET (right column) of a normal control (top row)
and an AD patient (bottom row). FDG: 2-[
18F]fluoro-2-
Deoxy-D-glucose, PIB: Pittsburgh Compound-B, AD: Alz-
heimer’s disease.  
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come these limitations, amyloid tracers labeled with fluor-
ine-18 (18F, 110 minute half-life) have been developed. The 
first fluorinated Aβ PET tracer to become available is 2-(1-
{6-[(2-[18F]Fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene) 
malononitrile (18F-FDDNP), which binds with high specifi-
city to both Aβ fibrils and NFTs.
98,99 
18F-FDDNP binding was 
elevated in AD and MCI patients as compared to healthy el-
derly, and showed uptake in the parieto-temporal, PCC, and 
frontal regions, yielding 100% diagnostic separation between 
AD and controls, and 95% between MCI and controls.
99 Mo-
reover, there was a strong correlation between tracer uptake 
and scores on tests of memory and global cognition, as well 
as longitudinal progression for a subgroup of non-demented 
subjects that deteriorated over 2 years.
99 One potential early 
diagnostic advantage of 
18F-FDDNP over PIB is its capacity 
to bind NFT in addition to Aβ plaques.
100 It is known that 
neurofibrillary tangle pathology, unlike Aβ deposition, ap-
pears in the early stages of disease in the hippocampal for-
mation
9 and increased NFT load in this region is associated 
with impairment of cognition.
101 One issue raised is the nar-
row range of tracer binding across subjects and subsequently 
low percentage change in binding across groups, ranging from 
5-8% increase in patients with MCI and AD relative to con-
trols.
100 Further studies are needed to assess the extent to 
which 
18F-FDDNP increases both early diagnosis and diag-
nostic specificity. 
Another fluorinated tracer for Aβ deposits, trans-4-(N-
methyl-amino)-4’-{2-[2-(2-[18F]fluoro-ethoxy)-ethoxy]-eth-
oxy}-stilbene (18F-BAY94-9172), has recently become av-
ailable.
102 
18F-BAY94-9172 binding matched the reported 
post mortem distribution of plaques, and was consistently hi-
gher in AD patients, as compared to healthy controls and FTD 
patients. Visual interpretation was 100% sensitive and 90% 
specific for the detection of AD.
102 
At the present time, amyloid imaging studies have not yet 
reported on early diagnosis, or on predictions of longitudinal 
clinical change. Additional validation studies are needed be-
fore Aβ PET imaging can enter into clinical practice. 
 
CSF biomarkers 
CSF is in direct contact with the brain and the molecular 
composition of CSF reflects biochemical changes in the cen-
tral nervous system. Consequently, many studies have ex-
amined the CSF as a possible source for biomarkers of AD 
pathology. Several candidate diagnostic biomarkers have em-
erged. The most widely studied CSF analytes include markers 
for tau [i.e., total (T-tau) and hyperphosphorylated tau (P-tau) 
proteins] and Aβ pathology (i.e., peptide fragments of Aβ40 
and Aβ42 amino-acid residues), as well as isoprostane (IsoP, 
a marker of lipid peroxidation and inflammation).  
CSF tau studies   
Two types of CSF measures for tau pathology have been 
used in AD: T-tau and markers for isoforms (X) of P-Tau (P-
TauX). T-tau, the first biomarker to be available, is the most 
widely used. Overall, CSF T-tau reflects both the normal me-
tabolism of tau and the nonspecific release of tau following 
neuronal damage, whereas P-tau231 reflects abnormal tau me-
tabolism that is both sensitive and specific for AD.
103 The 
evidence consistently demonstrates elevated CSF concentr-
ations of T-tau in AD and in MCI compared to NL controls.
104 
CSF T-tau is increased to around 300% in AD as compared 
to controls, probably as a result of neuronal and axonal dege-
neration, with a mean sensitivity of 84% and 91% specifi-
city.
105 Moreover, 11 studies show that CSF T-tau (and P-tauX 
in several studies) alone or in combination with Aβ42 predicts 
the conversion from MCI to AD.
106 Equivalent prediction ac-
curacies for CSF T-tau and P-tau231-235 were reported by 
Arai,
107 by Hansson using P-tau181,
108 and by our group
109 with 
P-tau231. However, reports about CSF X-tau levels in normal 
aging are limited and contradictory; some show age-related 
elevations in T-tau
110 and others do not.
111,112 Our adult lifes-
pan data shows age-related increases after age 60 for both P-
tau231 and T-tau, and both demonstrate additive ε4 related ef-
fects.
113 The T-tau level is not specific for AD, as CSF T-tau 
levels are also elevated in other neurodegenerative dise-
ases.
114,115 In acute stroke, the T-tau, but not the P-tau181 levels, 
were increased and later returned to normal.
116 However, P-
tau231 offers reasonable diagnostic specificity for AD. Hampel 
and his co-investigators found that the levels of P-tau231, but 
not T-tau, were consistently elevated in AD as compared with 
frontotemporal dementia (FTD), LBD, vascular dementia, and 
NL elderly controls.
117 More recent work extended the speci-
ficity of P-tau231 for AD to major depression
118 and CJD.
119 
Similarly, others demonstrated the advantage of P-tau181 over 
T-tau in comparisons between AD with FTD
120,121 and with 
non-AD dementias.
122,123 A recent longitudinal biomarker 
study using MRI showed that changes in the levels of P-
tau231 were longitudinally associated with the change in the 
hippocampal volume in MCI patients.
124 However, there is 
very limited evidence for CSF tau levels to increase with cli-
nical progression,
124,125 thus making the CSF measurement a 
potentially ancillary measurement to be used with modalities 
that do confer longitudinal information, such as FDG-PET or 
MRI. At present there are no reports of the combined use of 
tau biomarkers with FDG-PET in longitudinal designs. 
 
CSF Aβ studies   
CSF-Aβ42 is reduced in AD to around 50% of control con-
centrations, which may be due to the deposition of the peptide 
in brain plaques or to reduced neuronal production. Cross- 
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sectional CSF Aβ studies consistently show reduced Aβ42 
levels in both late onset AD
104,106 and MCI,
108,126 but there is 
a dearth of longitudinal data. The available longitudinal data 
show Aβ42 levels decrease in AD, but the magnitude of ch-
ange has limited diagnostic value.
115,127 The background ef-
fects of aging on CSF turnover and Aβ production and clear-
ance are poorly understood.
128-130 Peskind et al.
131 recently 
showed that CSF Aβ42 reductions were increasingly found 
with old age and detected at younger ages in ε4 carriers, and 
our data confirm that observation.
113 
Fagan recently reported that CSF Aβ42 reductions are asso-
ciated with PIB evidence for deposition, but that the relation-
ship is bimodal rather than linear.
93 CSF Aβ42 reductions pre-
dict decline from MCI to dementia
106 and from CDR=0 to 
CDR>0 when combined with T-tau or P-tau181.
132 To date, only 
one study importantly showed that high CSF T-tau/Aβ42 or 
P-tau181/Aβ42 ratios, but not X-tau or Aβx measures alone, pre-
dicted decline from CDR=0 (normal) to CDR>0 (impaired).
132 
The diagnostic utility of CSF Aβ40, a predominant feature 
of vascular amyloid, as an AD biomarker is less well under-
stood than Aβ42. A limited number of reports have shown 
elevated CSF Aβ40 levels with increasing age.
133,134 However, 
several cross-sectional studies failed to observe differences 
between AD and NL
135,136 and for this reason the Aβ42/40 ratio, 
controlling for overall Aβ production and clearance, is often 
used as a diagnostic marker.   
 
CSF isoprostane studies  
Oxidative stress is a recognized feature of AD and other neu-
rodegenerative diseases.
137 Postmortem studies by both the 
Pratico and Montine groups show elevated brain
138 and CSF 
IsoP levels
139 in AD. IsoP are isomers of enzymatically de-
rived prostaglandins, which are produced by O2 radical-ca-
talyzed peroxidation of polyunsaturated fatty acids.
140 Most 
AD work has focused on IsoP’s derived from prostaglandin 
F2α, which is a reliable marker of in vivo oxidative stress.
141 
These studies also demonstrate correlations between neuronal 
oxidation
138 and Braak staging.
139 There is a growing aware-
ness that IsoP changes are early features of AD that may even 
precede the development of fibrillar amyloid plaques.
142-144 
At postmortem CSF IsoP is elevated in MCI,
144 and there is 
consensus that the levels are elevated in both AD
145,146 and 
MCI in vivo.
124,147 In collaboration with Pratico, our CSF IsoP 
data show longitudinal elevations in MCI
124 that accurately 
predict the decline from MCI to AD.
109 Specifically, IsoP 
levels do change with clinical progression
109 and with pro-
gressive brain damage.
148 While there is no mechanistic basis 
to expect that elevated IsoP levels are AD-specific, several 
studies show that CSF IsoP levels are higher in AD than 
FTD
149,150 and other dementias.
151 
Combining PET with CSF biomarkers 
Unfortunately, there is not much literature examining CSF 
biomarkers and PET. We recently published the first study to 
examine the relationship in normal subjects with subjective 
memory complaints (SMC) between hypometabolism on 
FDG-PET and CSF markers of AD pathology.
79 Across all 
subjects, CMRglc in the MTL, parieto-temporal and frontal 
cortices were significantly correlated with CSF levels of T-
Tau, P-Tau231 and IsoP, while no significant relationships 
with PET were found between CSF Aβ40 and Aβ42. ApoE-4 
carriers with SMC showed the highest CSF T-Tau, P-Tau231 
and IsoP levels, and the lowest MTL CMRglc on PET, com-
pared to all other subgroups. These data indicate a relation-
ship between MTL CMRglc reductions, tau pathology and 
lipid membrane peroxidation in normal individuals at risk 
for late-onset AD, and suggest that the relationship between 
these biomarkers becomes tighter when subjects start to show 
memory deficits. Longitudinal follow-up examinations of 
these subjects are needed to determine whether the observed 
CSF and CMRglc abnormalities foreshadow clinical decline. 
 
Conclusions 
 
In recent years, several FDG-PET studies have shown that 
brain glucose hypometabolism in the hippocampal formation, 
combined with cortical abnormalities, is useful in accurately 
distinguishing AD from normal aging and, to some extent, 
from other dementias. These MTL changes can be found in 
both sporadic AD and early onset FAD individuals, even at the 
stages where patients are cognitively normal. For sporadic 
AD, this pattern of hypometabolism has also been reported 
among those at increased risk for AD, such as those with 
subjective memory complaints, carriers of the ApoE-4 geno-
type, and those with a maternal history of AD. Consequently, 
FDG-PET imaging is a candidate modality for detecting sub-
tle brain changes in early AD.   
There is considerable evidence that CMRglc is sensitive to 
progression effects
152 and can be used as outcome measure 
in long-term treatment studies of AD.
76,153 A major advantage 
of PET over other clinically based assessments, such as cog-
nitive performance, is the potential for reducing the sample 
sizes and study duration. It was estimated that, in order to 
detect a 33% treatment response with 80% power in a typi-
cal 1-year, double-blind, placebo-controlled treatment study, 
using the MMSE as endpoint would require 224 AD patients 
per group, whereas a minimal 36 patients per group would be 
needed for an FDG-PET study.
153 
Further longitudinal studies are necessary to examine whe-
ther the risk for developing a specific form of dementia can 
be predicted based on the detection of individual FDG-PET  
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patterns of CMRglc abnormalities among cognitively normal 
subjects or subjects with MCI. Currently, the AD Neuro-
imaging Initiative (ADNI) is pooling large amounts of longi-
tudinal data which may provide this opportunity in the future 
(see: http://www.loni.ucla.edu/ADNI/). 
There remains a great need to increase the preclinical diag-
nostic specificity, and to test whether the combination of the 
disease-sensitive CMRglc measures with pathology-specific 
biomarkers, such as with CSF measures of Aβ or tauopathy 
proteins, or amyloid PET imaging, would improve the dif-
ferential diagnosis of AD, prior to the onset of dementia.   
Accurate characterization of the extent and nature of brain 
damage in individual patients, based on converging evidence 
from different biomarkers, could play an important role in 
the prediction of subjects’ clinical course. Other potential 
benefits include the selection of individualized treatment plans 
and screening of patients with more uniform underlying pa-
thology for targeted research and drug trials. Overall, CMRglc 
FDG-PET measures predict cognitive decline from normal 
aging with sensitivity and specificity greater than 80%, and 
correlate with clinical progression in AD. CMRglc is there-
fore a promising candidate biomarker for AD.
19 Overall, PET 
imaging appears to be of great clinical importance to the 
early and differential diagnosis of Alzheimer’s type dementia. 
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